- Contribution of Radionuclide Theranostics for Managing Intractable Malignancies
-
Ahn BC
- KMID: 2414807
- Nucl Med Mol Imaging.
- 2018 Jun;52(3):168-169.
- doi: 10.1007/s13139-018-0526-9
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Heterogeneity Does Matter for Tumor Characterization
-
Lee WW
- KMID: 2414806
- Nucl Med Mol Imaging.
- 2018 Jun;52(3):167-167.
- doi: 10.1007/s13139-018-0525-x
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Incidental Detection of Peri-Renal Hemorrhage on F-18 FDG PET/CT Imaging in a Patient with Polycystic Kidney Disease
-
Kim MH, Kim DW
- KMID: 2414817
- Nucl Med Mol Imaging.
- 2018 Jun;52(3):243-246.
- doi: 10.1007/s13139-018-0513-1
A 72-year-old male patient with a history of polycystic kidney disease and lung malignancy underwent F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) for the evaluation of tumor recurrence. The... -
- CITED
-
- Close
- SHARE
-
- Close
- Radiomics in Oncological PET/CT: Clinical Applications
-
Lee JW, Lee SM
- KMID: 2414808
- Nucl Med Mol Imaging.
- 2018 Jun;52(3):170-189.
- doi: 10.1007/s13139-017-0500-y
¹â¸F–fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is widely used for staging, evaluating treatment response, and predicting prognosis in malignant diseases. FDG uptake and volumetric PET parameters such as metabolic... -
- CITED
-
- Close
- SHARE
-
- Close
- Survey Result of the Counting Efficiency of Gamma Counter by Certified Reference Materials
-
Bang JI, Lee HY, Noh GW, Park JM, Yoon JK
- KMID: 2414815
- Nucl Med Mol Imaging.
- 2018 Jun;52(3):234-237.
- doi: 10.1007/s13139-018-0515-z
PURPOSE: In radioimmunoassay (RIA), the gamma counter is the important instrument for the accurate measurement. To manage quality assurance of RIA, the counting efficiency of gamma counter is one of... -
- CITED
-
- Close
- SHARE
-
- Close
- Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives
-
Hirmas N, Jadaan R, Al-Ibraheem A
- KMID: 2414809
- Nucl Med Mol Imaging.
- 2018 Jun;52(3):190-199.
- doi: 10.1007/s13139-018-0517-x
PURPOSE AND METHODS: Patients with inoperable andmetastasized neuroendocrine tumors (NETs), particularly those with grades 1 and 2, usually receive treatment with somatostatin analogues (SSAs). Peptide receptor radionuclide therapy (PRRT) has... -
- CITED
-
- Close
- SHARE
-
- Close
- Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors
-
Kim K, Kim SJ
- KMID: 2414811
- Nucl Med Mol Imaging.
- 2018 Jun;52(3):208-215.
- doi: 10.1007/s13139-017-0505-6
Peptide receptor radionuclide therapy (PRRT) is a systemic cytotoxic radiation therapy using a compound of β-emitting radionuclide chelated to a peptide for the treatment of tumor with overexpressed specific cell... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of Bone Metastasis with Bone-Targeting Radiopharmaceuticals
-
Choi JY
- KMID: 2414810
- Nucl Med Mol Imaging.
- 2018 Jun;52(3):200-207.
- doi: 10.1007/s13139-017-0509-2
Bone is a common metastatic site of cancer. Bone metastasis reduces life expectancy and results in serious symptoms and complications such as bone pain, pathological fractures, and spinal cord compression,... -
- CITED
-
- Close
- SHARE
-
- Close
- Analysis of Iodine Content in Salts and Korean Sauces for Low-Iodine Diet Education in Korean Patients with Thyroid Cancer Preparing for Radioiodine Therapy
-
Kim SY, Park JM, Hwang JP
- KMID: 2414814
- Nucl Med Mol Imaging.
- 2018 Jun;52(3):229-233.
- doi: 10.1007/s13139-017-0511-8
PURPOSE: A low-iodine diet is necessary in patients about to undergo radioiodine therapy for thyroid cancer to decrease the competitive absorption of ingested nonradioactive iodine. This study aimed to assess... -
- CITED
-
- Close
- SHARE
-
- Close
- Incidental Detection of Parathyroid Adenoma on Somatostatin Receptor PET/CT and Incremental Role of ¹â¸F-Fluorocholine PET/CT in MEN1 Syndrome
-
Arora S, Damle NA, Passah A, Yadav MP, Ballal S, Aggarwal V, Gupta Y, Kumar P, Tripathi M, Bal C
- KMID: 2414816
- Nucl Med Mol Imaging.
- 2018 Jun;52(3):238-242.
- doi: 10.1007/s13139-018-0520-2
Multiple endocrine neoplasia type 1 (MEN1) syndrome is characterized by combined occurrence of tumors of endocrine glands including the parathyroid, the pancreatic islet cells, and the anterior pituitary gland. Parathyroid... -
- CITED
-
- Close
- SHARE
-
- Close
- A Single Intraperitoneal Injection of Endotoxin Changes Glial Cells in Rats as Revealed by Positron Emission Tomography Using [¹¹C]PK11195
-
Ota M, Ogura J, Ogawa S, Kato K, Matsuda H, Kunugi H
- KMID: 2414813
- Nucl Med Mol Imaging.
- 2018 Jun;52(3):224-228.
- doi: 10.1007/s13139-017-0510-9
PURPOSE: Intracranial administration of lipopolysaccharide (LPS) is known to elicit a rapid innate immune response, activate glial cells in the brain, and induce depression-like behavior. However, no study has focused... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluating the Predictive Ability of Initial Staging F-18 FDG PET/CT for the Prognosis of Non-HodgkinMalignant Lymphoma Patients Who Underwent Stem Cell Transplantation
-
Park YS, Lee SM, Park JS, Bae SK, Shim HK, Lee WS, Lee SM
- KMID: 2414812
- Nucl Med Mol Imaging.
- 2018 Jun;52(3):216-223.
- doi: 10.1007/s13139-017-0503-8
OBJECTIVES: This study aimed to determine the value of clinical prognostic factors and semiquantitative metabolic parameters from initial staging fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) in non-Hodgkin... -
- CITED
-
- Close
- SHARE
-
- Close
